Application of connectivity mapping in predictive toxicology based on gene-expression similarity.

Connectivity mapping is the process of establishing connections between different biological states using gene-expression profiles or signatures. There are a number of applications but in toxicology the most pertinent is for understanding mechanisms of toxicity. In its essence the process involves comparing a query gene signature generated as a result of exposure of a biological system to a chemical to those in a database that have been previously derived. In the ideal situation the query gene-expression signature is characteristic of the event and will be matched to similar events in the database. Key criteria are therefore the means of choosing the signature to be matched and the means by which the match is made. In this article we explore these concepts with examples applicable to toxicology.

[1]  John Deighton,et al.  Theimmunosuppressive drugthalidomide induces T helper cell type2(Th2) andconcomitantly inhibits Thlcytokine production inmitogen- and antigen-stimulat ed humanperipheral bloodmononuclear cell cultures , 1995 .

[2]  Tao Chen,et al.  Significance analysis of groups of genes in expression profiling studies , 2007, Bioinform..

[3]  Thomas T. Y. Wang,et al.  Stimulation of pS2 expression by diet-derived compounds. , 1994, Cancer research.

[4]  N. Navone,et al.  Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. , 1997, General pharmacology.

[5]  J. Epstein,et al.  Detection of Cardiac Allograft Rejection and Response to Immunosuppressive Therapy With Peripheral Blood Gene Expression , 2004, Circulation.

[6]  Shu-Dong Zhang,et al.  A simple and robust method for connecting small-molecule drugs using gene-expression signatures , 2008, BMC Bioinformatics.

[7]  TW Gant,et al.  Gene Expression Profiles Associated with Inflammation Fibrosis and Cholestasis in Mouse Liver after Griseofulvin , 2003, Environmental Health Perspectives.

[8]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[9]  I. Berlin,et al.  Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion , 2005, European Journal of Clinical Pharmacology.

[10]  C C Ting,et al.  Reversal of multiple-site tumor cell-induced immunosuppression by specific cytokines and pharmacological agents. , 1995, Immunopharmacology.

[11]  Roger G. Ulrich,et al.  Gene Expression Profiling of Multiple Histone Deacetylase ( HDAC ) Inhibitors : Defining a Common Gene Set Produced by HDAC Inhibition in T 24 and MDA Carcinoma Cell Lines , 2003 .

[12]  W. J. Silvia,et al.  Effect of an estrogen antagonist (tamoxifen) on cloprostenol-induced luteolysis in heifers. , 1988, Journal of animal science.

[13]  M L de Lemos,et al.  Effects of Soy Phytoestrogens Genistein and Daidzein on Breast Cancer Growth , 2001, The Annals of pharmacotherapy.

[14]  Shigeyuki Kitamura,et al.  Estrogenic activity of an antioxidant, nordihydroguaiaretic acid (NDGA). , 2004, Life sciences.

[15]  D. Edwards,et al.  17α-Estradiol Is a Biologically Active Estrogen in Human Breast Cancer Cells in Tissue Culture* , 1980 .

[16]  V. Armstrong,et al.  New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. , 2001, Clinical biochemistry.

[17]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.

[18]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[19]  M. Lishner,et al.  Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). , 2004, Reproductive toxicology.

[20]  P. Park,et al.  Discovering statistically significant pathways in expression profiling studies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Stolte,et al.  Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection , 1999, Alimentary pharmacology & therapeutics.

[22]  R. Tibshirani,et al.  On testing the significance of sets of genes , 2006, math/0610667.

[23]  P. Jagodziński,et al.  Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells. , 2007, International immunopharmacology.

[24]  A. Buzdar,et al.  Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. , 2004, Drugs of today.

[25]  Shu-Dong Zhang,et al.  sscMap: An extensible Java application for connecting small-molecule drugs using gene-expression signatures , 2009, BMC Bioinformatics.

[26]  H W Cole,et al.  Raloxifene is a Tissue‐Selective Agonist/Antagonist That Functions through the Estrogen Receptor , 1995, Annals of the New York Academy of Sciences.